News in brief: Cardiovascular risk with VEGFi and ICI combination therapy; DOAC underdosing in AF patients; Avoid stigmatising language in medical records;

VEGFi and ICI combination therapy will be accompanied by a substantial increase in cardiovascular risk The anticipated rise in VEGF inhibitors and immune checkpoint inhibitor combination therapy has prompted oncologists to warn of the cardiovascular toxicities associated with the anti-cancer therapies. Writing in Clinical Science oncologists and pharmacologists from Erasmus University Medical Center in the ...

Already a member?

Login to keep reading.

© 2021 the limbic